Close this search box.

Medical and Pharmacy Drug Management


The National Alliance is addressing topics affecting the pharmacy and medical side of benefits, especially the high cost of prescription drugs with the goal of driving better transparency and value on behalf of employers/purchasers.

Pharmacy and Medical Drugs

Defining and Driving Value

The National Alliance works with policymakers, employers/purchasers, and other stakeholders across the pharmacy and medical drug supply chain to influence competition, transparency and value. Current issues of focus include pharmacy benefit manager (PBM) performance, contracting and formulary management, biosimilars, reducing waste, pharmacogenomics, and value-based benefit design.

Medical and Pharmacy Drug Mangement Resources

The National Alliance supports policies to reduce prescription drug costs for all purchasers while encouraging meaningful innovation. These resources support employers/purchasers in injecting greater competition, transparency and value into pharmacy and medical drug management.


Prescription Digital Therapeutics (PDTs)

This PDT playbook for employers offers an overview of the digital health space, recommendations for evaluating and implementing a PDT strategy, and insight into the employer role in promoting PDTs.

Addressing Pharmacy Benefit Management Misalignment

High prescription drug costs continue to bankrupt families, put financial strain on businesses, and drag down the US economy and pharmacy benefit management plays a significant behind-the-scenes role. To arm employers and other plan sponsors with a blueprint to understand and navigate PBM relationships and strengthen their negotiating and contracting capabilities, the National Alliance has developed this playbook for purchasers.

Employers’ Prescription for Affordable Drugs (EmployersRx)

EmployersRx supports policies that would require PBMs to make pricing data available to payers and compel drug companies to report and justify price increases for some medications. This coalition also seeks to strengthen competition and remove barriers that stifle the development and use of generic drugs and biosimilars.

Employer Playbook on Biosimilars

This playbook grapples with how best to integrate biologics into health and pharmacy benefit plans. The National Alliance has developed this playbook to provide clear information to inform conversations with health plans and other vendor partners.
Health Policy Document

Prescription Drug Provisions in the Inflation Reduction Act of 2022

This Health Policy in Transit is a high-level summary of the prescription drug provisions contained in the Inflation Reduction Act. It also describes the decision made by the Senate Parliamentarian to exclude commercial plans from the inflation rebate provision, and how this will potentially affect employer plan sponsors.

Improving Drug Management

Reduced barriers to biosimilar adoption could generate savings of about $25 billion over 10 years, or roughly 0.5% of national spending on prescription drugs. However, other organizations indicate biosimilars savings could project upwards of $133 billion by 2025, but only if policymakers encourage greater biosimilar adoption. A summary of employer roundtables offers insights into overcoming biosimilar barriers.

Opportunities in Pharmacy Benefit Management

PBMs are under considerable scrutiny today, but the organizations in this white paper have demonstrated a willingness to open their actions to analysis. This guide helps employers/purchasers open discussions with current or prospective PBMs.

Findings on the State of the PBM Industry

This 2020 Report includes a cross-section of PBMs. For the first time, this report publicly identifies the participating PBMs’ comparisons in graph form. It also includes educational articles, ranging from opioid treatment to maximizing PBM audits, and understanding copay assistance programs.
Action Brief

Biosimilars in the Pharmacy Benefit

Despite the fact that less than 2% of the population uses biologic drugs, they account for 26% of national prescription drug spending. Biosimilars can expand options, improve affordability, and increase access to therapy.

Coalitions In Action

Membership in the National Alliance is a catalyst for state and regional coalitions and their employer/purchaser members to advance key initiatives. Together, they leverage their collective influence to drive health, equity and value.

Related News & Resources